Answers are grounded in this paper and cite their sources.
Background/Aims: Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder with limited population-based epidemiological data. We estimated the nationwide incidence and prevalence of AOSD in South Korea and assessed temporal trends. As a secondary exploratory aim, we also examined claims-based treatment trajectories. Methods: We conducted a nationwide retrospective cohort study using Korean National Health Insurance Service claims data from 2002 to 2022. Annual incidence and prevalence were age- and sex-standardised to the 2019 Korean population. Temporal trends were evaluated using log-linear regression and one-joinpoint analyses. Patients were additionally grouped according to claims-based medication trajectories. Results: Among 15,000 individuals with an AOSD diagnostic code, 4,825 met the case definition; 4,600 incident cases diagnosed during 2003-2022 were included. Age- and sex-adjusted annual incidence remained below 1 per 100,000 population (0.28-0.75), with no significant overall temporal change (annual percent change [APC], 1.41%; 95% confidence interval [CI], -0.58 to 3.44; p = 0.155). Age- and sex-adjusted prevalence increased from 0.91 per 100,000 in 2003 to 10.02 per 100,000 in 2022 (APC, 12.51%; 95% CI, 10.56 to 14.50; p < 0.001). Across successive 5-year periods, the proportion of female patients decreased from 72.9% to 66.1%, whereas mean age at diagnosis increased from 41.7 to 47.5 years. Under prespecified operational rules, 3.0% of patients were grouped as monocyclic, 39.6% as polycyclic, 17.7% as chronic, and 39.6% as unclassified. Conclusions: AOSD in South Korea is rare, with low overall incidence but steadily increasing prevalence. Exploratory treatment trajectory analyses may complement population-level epidemiological assessment.
No takes yet. Share an insight, caveat, or question.
Kwon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: